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USE OF ANTIMICROBIALS BY PREGNANT WOMEN 
IN THE PUBLIC HEALTH CARE
Uso de antimicrobianos por gestantes no serviço público de 
saúde
Uso de antimicrobianos por embarazadas del servicio público 
de salud
ABSTRACT
Objective: To identify and classify, according to the risk, the antimicrobials prescribed to 
pregnant women assisted by the National Program of Prenatal and Postpartum Follow-up in 
a municipality of Rio Grande do Sul. Methods: Analytical and retrospective cross-sectional 
study conducted in 2011 based on the registers of 87 pregnant women assisted in 2010 using 
an instrument with questions about the dispensed drugs. The prescribed antimicrobials were 
identified and classified as topical and systemic use and according to the risk of using it 
during pregnancy. Data were analyzed using SPSS 15.0. Results: The pregnant women had a 
mean age of 28.01 years and attended 5.3 consultations. There was an average prescription of 
6.52 drugs/pregnant woman. Of the 568 drugs prescribed, 85 (14.96%) had an antimicrobial 
activity, 29 (34.1%) were for topical use and 56 (65.9%) for systemic use, and 46 (52.9%) 
pregnant women received at least one antimicrobial. There were 13 different products with 
a prevalence of antifungals of gynecological / topical use, 16 (18.82%), 30 (35.3%) were 
prescribed in the first trimester of pregnancy, 30 (35.3%) in the second and 25 (29.4%) in 
the third trimester. According to the classification of the risk to the fetus, nine (61.54%) 
antimicrobials belonged to the B category and four (30.77%) to the C category. Conclusion: 
It was verified the prescription of antimicrobials for systemic use and B category risk for 
pregnancy to 52.9% of pregnant women in prenatal follow-up in the place where the study 
took place. Miconazole and metronidazole vaginal cream, cephalexin 500 mg, azithromycin 
500 mg and amoxicillin 500 mg were the most prescribed drugs.
Descriptors: Anti-bacterial Agents; Drug Utilization; Pregnancy.
RESUMO
Objetivo: Identificar e classificar quanto ao risco os antimicrobianos prescritos para 
gestantes atendidas no Programa Nacional de Acompanhamento Pré-Natal e Puerpério em 
um município do Rio Grande do Sul. Métodos: Estudo transversal analítico e retrospectivo, 
realizado em 2011, a partir do cadastro de 87 gestantes atendidas em 2010, por meio de um 
instrumento com questões relacionadas aos medicamentos dispensados. Os antimicrobianos 
prescritos foram identificados e classificados como de uso tópico e sistêmico, e quanto à 
categoria de risco de uso na gravidez, com tratamento realizado pelo SPSS 15.0. Resultados: 
As gestantes tinham idade média de 28,01 anos, realizaram 5,3 consultas. Foram prescritos 
em média 6,52 medicamentos/gestante, dos 568 medicamentos prescritos, 85 (14,96%) com 
ação antimicrobiana, 29 (34,1%) de uso tópico e 56 (65,9%) uso sistêmico, sendo que 46 
(52,9%) gestantes receberam pelo menos um antimicrobiano. Encontrou-se 13 produtos 
distintos, prevalecendo antifúngicos de uso ginecológico/tópico, 16 (18,82%), 30 (35,3%) 
foram prescritos no primeiro trimestre de gravidez, 30 (35,3%%) no segundo e 25 (29,4%) 
no terceiro. Conforme a classificação de risco ao feto, nove (61,54%) antimicrobianos são 
da categoria B e quatro (30,77%) da categoria C. Conclusão: Verificou-se a prescrição de 
antimicrobianos de uso sistêmico e de risco B na gestação para 52,9% das gestantes em 
acompanhamento pré-natal no local do estudo. Miconazol e metronidazol creme vaginal, 
cefalexina 500 mg, azitromicina 500 mg e amoxicilina 500 mg foram os mais prescritos.
Descritores: Antibacterianos; Uso de medicamentos; Gravidez.
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RESUMEN
Objetivo: Identificar y clasificar el riesgo de los antimicrobianos 
prescritos a las embarazadas asistidas en el Programa Nacional 
de Atención Prenatal y Puerperio en el municipio de Rio Grande 
do Sul. Métodos: Estudio transversal analítico y retrospectivo 
realizado en 2011 con el registro de 87 embarazadas asistidas em 
2010 a través de un instrumento con preguntas relacionadas a 
los medicamentos dispensados. Los antimicrobianos prescritos 
fueron identificados y clasificados de uso tópico y sistêmico 
y respecto la categoría de riesgo del uso en el embarazo, com 
análisis realizado por el SPSS 15.0. Resultados: Las embarazadas 
tenían edad media de 28,01 años y realizaron 5,3 consultas. 
Fueron prescritos una media de 6,52 medicamentos/embarazada, 
de los 568 medicamentos prescritos, 85 (14,96%) con acción 
antimicrobiana, 29 (34,1%) de uso tópico y 56 (65,9%) de uso 
sistémico, siendo que 46 (52,9%) de las embarazadas recibieron 
por lo menos un antimicrobiano. Se encontró 13 productos 
distintos con prevalencia de anti fúngicos de uso ginecológico/ 
tópico, 16 (18,82%), 30 (35,3%) fueron prescritos en el primer 
trimestre del embarazo, 30 (35,3%%) en el segundo y 25 (29,4%) 
en el tercero. Según la clasificación de riesgo al feto, nueve 
(61,54%) antimicrobianos son de la categoría B y cuatro (30,77%) 
de la categoría C. Conclusión: Se verificó la prescripción de 
antimicrobianos de uso sistémico y de riesgo B en el embarazo 
para el 52,9% de las embarazadas en atención prenatal en el sitio 
del estudio. Miconazol y metronidazol crema vaginal, cefalexina 
500 mg, azitromicina 500 mg y amoxicilina 500 mg fueron los más 
prescritos.
Descriptores: Antibacterianos; Utilización de Medicamentos; 
Embarazo.
INTRODUCTION
The use of medicines by pregnant women and its 
consequences for children who will be born has become a 
big concern after events occurring between the late 50’s and 
early 60’s (1).
Gestation, for its biological peculiarities, turns the 
woman and her fetus particularly exposed to risks, among 
which stand out the relationship to the use of medications(2). 
The fetal response to the use of medicines is different from 
that observed in the mother and may result in fetal toxicity, 
with various injuries, some of which may be irreversible (3).
The use of drugs during pregnancy should be avoided, 
however, in some situations, such use is essential(4), 
becoming possibly harmful to women with chronic diseases 
or suffering medical complications during gestation(5). 
The information about the risks of the use of medicines 
during pregnancy are quite limited, regarding both quantity 
and quality aspects, which is mainly due to ethical and 
methodological difficulties of this research area(4). 
Information about the risk of using drugs during 
pregnancy are scarce, its indiscriminate use due to self-
medication or medical prescriptions without technical-
scientific criteria is reported in different countries(1). A 
study on high-risk pregnant women showed statistically 
significant associations between self-medication in women 
with fewer prenatal consultations, smoking during gestation 
and bigger number of children(6).
Considering that, during gestation, urinary tract 
infections (UTI) are quite common, with up to 10% of 
pregnant women experiencing an episode of urinary tract 
infection, being mostly asymptomatic(4), the prescription 
of antimicrobial drugs in this period is justified. In a 
study(7) that analyzed prescriptions for pregnant women 
admitted to a hospital in the municipality of Mirassol/SP, 
antimicrobials were present in 40% of the prescriptions, 
and the most prescribed were cephalothin (10.8%) and 
cephalexin(4.6%). In another study(8) concerning pregnant 
women who attended consultations in the prenatal service 
of the Sistema Único de Saúde – SUS (Unified Health 
System) in six Brazilian cities, antimicrobials were used by 
11.1% of pregnant women, accounting for 6.9% of the used 
medications.
In addition to the increased incidence of UTI and 
other infections in pregnant women,  during this period 
the antimicrobial prophylactic and therapeutic options are 
limited, considering the toxicity of the drugs to the fetus(9).
In this context, it is highlighted that the greatest amount 
of the medicines with antimicrobial action, according to 
the fetal risk rating system, belongs to the category B(4), 
indicating that studies have been conducted in animal 
reproduction using these drugs showing no fetal risks, 
however, lacking controlled studies in pregnant women or 
animal reproduction studies demonstrating adverse effects 
that were not confirmed in controlled studies in women in 
the first trimester, but without evidence of risk in the other 
trimesters(10).
Given the above, the objective of this study was to 
identify and classify, according to the risk, the antimicrobials 
prescribed to pregnant women assisted by the National 
Program for Prenatal and Postpartum Follow-up in a 
municipality of Rio Grande do Sul.
METHODS
A cross-sectional and retrospective study was 
performed on the analysis of prescriptions for pregnant 
women assisted by the National Program of Prenatal and 
Postpartum Follow-up in a Unidade Básica de Saúde Central 
- UBS – Central (Central Basic Health Care Unit) and in the 
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Centro de Atendimento aos Adolescentes – CAAMI (Center 
for Adolescents’ Assistance) of the Municipality of Ijuí/RS 
in 2010.
Data collection occurred with access to all medical 
records of pregnant women attended in the areas included 
in the research in early 2011, with the aid of a data 
collection instrument that contained questions related 
to the socioeconomic characteristics of these as well as 
the dispensed drugs for pregnant women at these places. 
Data collection was executed by trained researchers and 
information was obtained from two places: UBS-Central 
and CAAMI from the Municipality of Ijuí/RS, through 
access to the medical records of pregnant women and the 
computerized system for drug dispensation existing at these 
sites. Data collection was optimized by the creation of an 
instrument that was filled by a researcher and subsequently 
validated by another. On average, 20 records were analyzed 
per day.
All pregnant women attended in the above places 
receiving at least the prescription of one medication were 
included in this study. Non-pregnant women, pregnant 
women who did not receive any prescription drug and 
pregnant women assisted by other health units from the 
municipality were excluded. 
The prescribed antimicrobial drugs were identified 
by its generic name and pharmaceutical form, allowing its 
classification as either a topical or a systemic use.
Antimicrobials were also grouped according to the risk 
category of use in gestation according to the Food and Drug 
Administration (FDA), described as follows: Category A: 
studies in women showed no risk to the fetus in the first 
trimester and the possibility of injury to the fetus seems 
remote; category B: Animal reproduction studies have not 
demonstrated fetal risk but there are no studies in pregnant 
women, or studies in animal reproduction demonstrating 
adverse effects were not confirmed in studies in women 
in the first trimester; category C: studies in animals have 
shown adverse effects on the fetus and there are no studies in 
women or studies in women and animals are not available. 
The drugs should be used only if the potential benefit 
justifies the potential fetal risk; category D: there is positive 
evidence of human fetal risk, but the benefits from its use 
in gestation may be acceptable despite the risk; category 
X: studies in animals or humans have demonstrated fetal 
abnormalities or there is evidence of fetal risk based on 
human experience or both, and the risk of the drug use in 
pregnant women clearly exceeds any possible benefit(11).
 Data interpretation was performed according to 
the total number of medications used by pregnant women, 
identification and quantification of antimicrobials, as well 
as the gestational period in which they were prescribed, 
analyzing the risk/benefit of such use during the period. This 
analysis was conducted through a descriptive approach, 
with mean and standard deviation, being held a correlation 
between the number of medications and the number of 
medical consultations by Spearman’s correlation, being the 
statistical treatment elaborated by the Statistical Package 
for the Social Sciences software (SPSS) (version 18.0).
The research was approved by the Unijuí Research 
Ethics Committee under protocol 153/2011. The access to 
the database was obtained after authorization at the local 
of the survey, and researchers and those responsible for the 
surveyed areas have signed a non-disclosure agreement, 
ensuring the confidentiality of data.
RESULTS 
The sample comprised of 87 pregnant women who 
had prenatal care, all assisted by the SUS. The mean age of 
pregnant women was 28.01 ± 6.61 years old. Regarding age 
group, 41 (47.13%) were aged 20-29 years (Table I).
Table I - Distribution of assisted pregnant women during 
the study period according to age group attended at the UBS 
Central and CAAMI in the municipality of Ijuí-RS in 2010. 
Ijuí/RS, 2011.
Age Group n (%)
16 – 19 12 (13.79)
20 – 29 41(47.13)
30 – 39 29 (33.33)
≥ 40 years 5 (5.75)
Total 87 (100)
The mean of consultations by pregnant women was 
5.3 ± 3.01. Table II displays the total amount and the 
mean number of medicines prescribed to pregnant women 
in relation to the number of prenatal visits, however, the 
Spearman’s correlation coefficient revealed a significant 
weak positive correlation (r=0.281; p=0.008) between the 
number of consults and the number of medications, although 
no association being found between those variables.
It was found the prescription of 568 medications, a 
mean of 6.52 medications/pregnant women. Out of these, 
85 (14.96%) have antimicrobial action, being 194 (34.1%) 
topical, and 374 (65.9%) for systemic use. 
From the 85 prescribed antimicrobials, there were 
13 specific products. The most frequently prescribed 
antimicrobials were miconazole vaginal cream, cephalexin 
500 mg, metronidazole vaginal cream, azithromycin 500 
mg and amoxicillin 500 mg.
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From all women who used medications during 
pregnancy during the study period 46 (52.9%) received 
antimicrobial prescriptions.
It is noteworthy that among the 46 women who received 
prescription containing antimicrobials during gestation, it 
was prescribed one antimicrobial to 24 (54.4%) women, 
two to 10 (21.7%), three to 6 (13,1%), four to 3 (6.5%) 
and more than five to 2  women (4.4%). Note that these 
numbers do not refer to the concomitant use but throughout 
the gestation period.
Table III presents the trimester in which the studied 
pregnant women received antimicrobials, being observed 
that the gynecological products were the most prescribed 
ones.
Concerning the antimicrobials prescribed for pregnant 
women, it was found that eight (61.54%) antimicrobials 
belonged to category B and four (30.77%) from category 
C, according to the risk category established by the FDA.
Table II - Number and mean of medications used by pregnant women in relation to the number of prenatal consultations 
assisted at the UBS Central and CAAMI in the municipality of Ijuí-RS, in 2010. Ijuí/RS, 2011.
Consultations  Pregnant Women n(%) Medications n(%)  Medications/pregnant women mean
≥ 3 19 (21.84) 106 (18.66) 5.58
4 – 6 25 (28.74) 144 (25.35) 5.76
7 – 9 29 (33.33) 206 (36.27) 7.10
≥ 10 14 (16.09) 112 (19.72) 8
Total 87 (100) 658 (100)                     
Spearman’s Correlation: r=0.281; p=0.008.
Table III - Distribution of pregnant women according to the prescribed antimicrobial drug and gestational period attended at 
the UBS Central and CAAMI in the municipality of Ijuí-RS, in 2010. Ijuí/RS, 2011.
Antimicrobial           1st trimester          2nd trimester  3rd trimester Total  
  (n%) (n%) (n%) products
Miconazole VC* 2% 16 (20) 7 (23.33) 3 (12)  16 (18.82)
Cephalexin 500 mg 2 (6.67) 7 (23.33)  4 (16) 13 (15.29)
Metronidazole  VC 5 (16.67) 4 (13.33) 3 (12) 12 (14.12) 
Azithromycin 500 mg 2 (6.67) 4(13.33) 5 (20)  11(12.94)
Amoxicillin 500 mg 6(20) 3 (10.01) 2 (8) 11(12.94)
Metronidazole 250 mg 2 (6.67) 2(6.67) 3(12) 7 (8.24)
Fluconazole 150 mg 4(13.33) 2(6.67) - 6 (7.06)
Sulf. 400mg/trim.80 mg**  - 1(3.33) 3 (12) 4 (4.71)
Others 3 (10) - 2 (8) 5 (5.88)
Total 30(100) 30 (100) 25 (100) 85 (100)
*VC= vaginal cream; **sulfamethoxazole-trimethoprim;***Spearman’s correlation r=0.281; p=0.008.
DISCUSSION
Pregnant women are often exposed to medicines(12). A 
research conducted in São Paulo comprising 1,581 women 
showed that 97.6% of them used at least one medication 
during gestation and 2.2% used more than ten, with a mean 
of 4.2 drugs per woman(3). From 100 women who received 
prenatal care at SUS services in Santa Rosa/RS, 90% used at 
least one medication during pregnancy, totaling 371 items, 
being the mean 4.1 drugs/pregnant women(12). One study 
evaluated the prescription drugs to pregnant women in five 
UBS’s of the municipality of Ijuí/RS, finding a mean of 3.5 
drugs prescribed by pregnant woman(13), corresponding to 
half of the mean of drugs prescribed in this present study 
202 Rev Bras Promoç Saúde, Fortaleza, 27(2): 198-206, abr./jun., 2014
Fritzen JS, Colet CF, Oliveira KR
(6.5 drugs/pregnant women), indicating that the pregnant 
women from our research sites had more complications 
during gestation.
In a study performed in Ijuí/RS(13), it was noticed 
that most of the pregnant women (47.9%) had from 7 up 
to 9 prenatal consultations, being the same number of 
appointments practiced by 33.33% of the women from this 
current study. The number of prescription drugs was related 
to the number of consultations(13) and, such as another 
research(11) held in Santa Rosa/RS, it was found that the 
number of prescription drugs increases with the number 
of consultations. In this sense, it is suggested(12) that the 
prenatal care of pregnant women facilitates the access to 
medications. 
Accordingly, despite the avoiding of the unnecessary 
use of drugs in this population(4), this result reflects the use 
of medications during gestation as a frequent practice in the 
UBS studied. It is recommended(13) that before handling any 
medication during pregnancy, the pregnant woman and the 
prescriber should discuss its nature, the possible effects on 
the fetus and if its use is absolutely necessary. Ideally, the 
administration of any kind of medication during gestation 
should be averted, which rarely occurs(14).
Regarding the number of prenatal consultations, the 
mean number was 6.2(15) in Caxias do Sul/RS, which is 
close to the value found in this study, where approximately 
5.3 appointments by pregnant woman were achieved. In a 
study(13) conducted in Ijuí/RS, among the five studied UBSs, 
the central unit is pointed out, which was also included in 
this present study. That research(13), showed that in 2008, 
the mean of appointments was 5.8, with a mean of 3.3 
medications dispensed by pregnant women, numbers that 
remained stable during 2010, as verified by the current 
study. 
Women are being encouraged to perform prenatal 
care and are responding to that call(10). The prenatal care 
schedule must be programmed depending on the gestational 
periods that determine higher maternal and perinatal risk, 
achieving at least six appointments, preferably one in 
the first trimester, two in the second and three in the last 
trimester. The higher frequency of visits in late pregnancy 
aims the evaluation of perinatal risk and clinical and 
obstetric complications more common in this trimester, such 
as preterm labor, preeclampsia and eclampsia, premature 
rupture of membranes and fetal death (16).
Accordingly, the healthcare actions implemented by 
the prenatal care program should be directed to comprise 
the entire target population of the area covered by the 
healthcare unit, ensuring the continuity of care, monitoring 
and evaluation of these actions on maternal and perinatal 
health. The Ministry of Health is responsible for establishing 
policies and technical standards for the prenatal care of 
good quality. In addition to the necessary equipment and 
instruments, one should take into account the capacity of 
the health team(17).
On the other hand, it is pointed out that prenatal 
appointments have facilitated the access of pregnant women 
to medications. A study on the social and psychological 
function of prescription drugs shows that for the doctor, 
the prescription is not only the documentation for his 
intervention in order to change the course of a disease or 
eliminate a symptom, but it is a sign of care to the patient(18). 
Not receiving a medical prescription may be interpreted as 
disinterest and even medical incompetence, representing the 
breakdown of the doctor’s relationship with its customers(18).
Antibiotics for systemic use were prescribed 
approximately four times more than in a survey(18) held in a 
teaching hospital in São Paulo, which found that systemic 
antibiotics were used by only 15.8% of patients.
In a study(8) held in SUS prenatal services in six 
Brazilian cities, it was observed that 11.1% of pregnant 
women were prescribed antimicrobials, corresponding to 
6.9% of the medicines used by them. The most commonly 
prescribed groups were penicillins (40%), tetracyclines 
(30%) and sulfonamides associated with trimethoprim 
(11%). Another investigation(13) found that 13.90% of 
prescription drugs for pregnant women were anti-infectives 
for systemic use, being the third most prescribed anatomical 
group, with similar results found in Santa Rosa(12), where 
the anti-infectives represented 14.2% of prescription drugs. 
A study performed to assess the quality of antimicrobial 
use by pregnant women in a hospital in Cuba between 
2007- 2009 pointed out that vaginal sepsis was the disease 
that most led to its use, mostly having a clinical diagnosis 
and the most prescribed antimicrobials were azithromycin, 
metronidazole, clotrimazole and nystatin(19).
The systemic antibiotics most often prescribed to 
pregnant women in this research were penicillins and 
cephalosporins, which, according to a study(20), act interfering 
with the synthesis of peptidoglycan in the bacterial cell 
wall after binding to β-lactam binding proteins. These 
antibiotics are safe and commonly prescribed to pregnant 
women, including cephalexin, ampicillin/amoxicillin and 
nitrofurantoin(20). Antibiotics that act by inhibiting cell 
wall synthesis offer lower side effect risks, allowing its use 
with great safety in pediatrics, gestation and lactation(21). 
The above antimicrobials are among the drugs of choice in 
prenatal care, childbirth and postpartum period(16).
Regarding the most prescribed antimicrobials to 
pregnant women studied in the present research, 30 (35.3%) 
were prescribed in the first trimester of pregnancy, 30 
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(35.3%) in the second and 25 (29.4%) in the third trimester. 
The inherent risks of the use of drugs during pregnancy can 
occur at any stage, however, the drugs have more intense 
effects when administered during the first trimester(14), 
mainly between the 3rd and the 11th week (11). It is believed 
that during the period of fertilization and implantation 
(up to 17 days), toxic drugs can interrupt the gestation or 
not cause any effect. In the organogenesis period (18-56 
days), the susceptibility to malformation is maximum and 
during the fetal period (from the 56th day on), the risk of 
morphological malformations is low. However, harmful 
substances administered during this period may cause 
functional organic changes, and also, behavioral, social and 
intellectual alterations.(4)
 In order to guide the prescriber for the most appropriate 
therapeutic choice for a pregnant woman, the FDA 
classified the medications as its effects on pregnancy in risk 
categories(11). According to this classification, it was found 
in this study the prescription of category B antimicrobials 
to eight patients (61.54%), four (30.77%) of category C and 
none from categories D and X. It should be highlighted that 
no antimicrobials were classified into category A. These 
results reveal that the most prescribed antimicrobials for 
pregnant women are from category B, which is consistent 
with other studies(5;13).
The medications from the risk category C were the 
second most prescribed medications in another study(13), 
which was also demonstrated in this investigation. 
Nevertheless, the  predominant risk category in both 
investigations was B.
Considering the great use of risk category C 
antimicrobials, it is drawn attention to the need to review 
the issued prescriptions to this group, since this category 
hold drugs in which studies were done on animals, 
revealing adverse effects on the fetus(10). It is important 
to consider that the data obtained from animal studies can 
not be fully extrapolated to human pregnancy(14). In this 
category are found antimicrobials for systemic use, like 
fluconazole, which was prescribed to five (5,75%) pregnant 
women from the current research. This medication presents 
an antifungal action and uncommon adverse reactions, 
including gastrointestinal disorders, headache, or, more 
rarely, hepatotoxicity and thrombocytopenia(22), and even 
abortion, augmentation of labor and fetal abnormalities in 
animals studies of fluconazole use(22).
Miconazole for gynecological use, the most prescribed 
drug in this study, is an azole derivative of broad spectrum 
of action(22), acting by the inhibition of ergosterol synthesis, 
an essential component of the fungal cell membrane(4). 
It is a tissue amoebicide and has been the first choice for 
Entamoeba histolytica active infection cases, with an 
estimated efficacy of 90%(21). Its systemic use was virtually 
abandoned due to its toxicity(4). Miconazole, in its various 
pharmaceutical forms, is the only antifungal incorporated 
to the list of drugs used in the prenatal, delivery and 
postpartum period, probably due to its reduced systemic 
effects (vaginal 1.4% and dermal less than 0.013%)(15), 
which turns it less toxic.
The selection of an antibiotic for topical use is based 
primarily on its spectrum of action, on the etiology of the 
infection and on the possibility to lead to primary irritant 
reactions or sensitization. However, it is remarkable 
that topical antibiotics hold certain drawbacks that limit 
their indications, including the time elapsed until the 
pharmacological effect is set and the factors influencing its 
absorption, as the concentration and the nature of the active 
ingredient, the skin state and the vehicle behavior(22).
From the total of pregnant women investigated in this 
study, 6.89% received antimicrobial prescriptions belonging 
to risk category C during the first trimester of pregnancy. 
This drug class must be avoided in the first trimester 
because of the risks of congenital abnormalities(10). Thus, 
it is suggested that pregnant women who will inevitably 
make use of drugs belonging to this category of risk during 
pregnancy are accompanied during the period of its use and 
the achieved results are recorded so they can be socialized 
and compared in order to benefit other women who might 
be in the same situation(23).
By reviewing category B antimicrobials used in this 
research, emphasis is laid on the following: cephalexin, 
azithromycin, and amoxicillin. The indication of these 
medications is justified because they are antimicrobial 
agents that may be indicated for gestational use due to 
their high selective toxicity and low potential for toxicity 
to the pregnant woman and fetus(7). Cephalexin was the 
most prescribed systemic antibiotic (14.12%) for pregnant 
women studied in the current research. Another study(12) 
refers to cephalexin as the fourth most prescribed drug 
(19.3%) in a study conducted in the same municipality, 
also comprising of pregnant women attended by the public 
health service.
Nitrofurantoin belongs to that same category of risk 
and may lead to neonatal hemolysis from the third trimester 
on(10). In the current study, this drug has been prescribed to a 
woman in the second trimester of pregnancy.
It was not found any dispensing records in the electronic 
investigation regarding the use of antimicrobials belonging 
to risk categories D and X, which can be justified by the 
small number of drugs belonging to these classes. The 
lacking of medications from these categories is possibly 
related to the fact that standardized medications by the 
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Ministry of Health for this group (pregnant women) do not 
belong to these categories(16).
During the gestational period, the UTI is the most 
common infection, with up to 10% of pregnant women 
being affected by an episode of urinary tract infection, 
mostly asymptomatic(4). The microorganisms involved in 
about 80 to 90% of these infections come from the normal 
perineal flora. The gram-negative, such as Klebsiella, 
mainly Escherichia coli, Enterobacter and Proteus 
account for most other cases, in addition to enterococci 
and group B streptococcus. Asymptomatic bacteriuria is 
the most frequent. Additionally, symptomatic infections 
affecting the lower urinary tract (cystitis) or the upper tract 
(pyelonephritis)(16)  are also common complications in this 
group(4).
A research(13) also found no medications from risk 
category X prescribed to pregnant women in other UBS’s 
from Ijuí/RS. There is an investigation(17) that evaluated 
medications prescribed to pregnant women and their 
self-medication practice, that found the use of a proven 
teratogenic drug from this category (misoprostol), which 
had been used in an attempt to cause abortion. However, 
another research(8) that verified the fetal risks through 
prescriptions of pregnant women in São Paulo noticed a 
high rate of category X drugs (3.5%).
Considering the risk categories where drugs are 
inserted and gestational trimesters, prescriptions containing 
risk category B drugs were assigned during all gestational 
periods in this current research. In this category are included 
medicines that showed no fetal risk in animal reproduction 
studies; or animal reproduction studies demonstrated 
adverse effects that were not confirmed in controlled studies 
in women in the first trimester (and there is no evidence of 
risk in other trimesters), requiring some caution regarding 
the prescription of these drugs(11). In this current study, only 
one medication for gynecological use from risk category C 
antimicrobials was prescribed in all three trimesters, being 
the others prescribed only in the first and second trimesters, 
which is not in accordance with the literature(10), because 
some of the medicines from that category of risk should be 
avoided in the first trimester of gestation due to the risk of 
causing congenital abnormalities.
In this investigation, like others carried out in 
Brazil(3,5,13,15), the majority of pregnant women were aged 
20-29 years. However, according to a study from 2008 
in Caxias do Sul/RS, pregnancy rates in adolescence are 
still high, totaling 26.2% for those aged under 20 years(15). 
Another study(13) also held in a UBS in Ijuí/RS found only 
six (3.5%) pregnant women aged 14-19 years, moreover, in 
our study, we found 12 (13.79%) in this age group.
There is no doubt that pregnant women are frequently 
exposed to medications as a result of typical complications 
of this period. Infections represent a relative source of 
maternal complications, reflecting on the prescription and 
the use of antimicrobials. The access to prenatal care and 
antibiotics for those pregnant women does not necessarily 
imply better health conditions or quality of life, because 
bad prescription habits, often unnecessarily, or even lacking 
information about some antibiotics can lead to unsafe 
treatments for both pregnant women and fetus(24).
The presented results show the need for actions that 
aim the promotion of knowledge related to the use of 
medications during the gestational period, as it is extremely 
important that the health-care professional team is aware of 
medications that can be used for that group, not exposing 
them to injuries or risks. The planning of educational 
interventions for pregnant women in order to discourage 
self-medication and update activities for health professionals 
seem essential for a gestation with quality, minimizing fetal 
risks. It is important to highlight that there was no contact 
with the pregnant women, limiting the access to some 
information, such as the use of prescription drugs that were 
dispensed in other places rather than in the municipal health 
pharmacy network, the use of non-prescription drugs, as 
well as the use of medicinal plants, representing a limitation 
of this study. Accordingly, it is emphasized that each one 
of these practices further exposes the pregnant woman and 
the fetus to risks related to the individual effect of the used 
medications and their interactions.
CONCLUSION
Antimicrobial medications were identified among 
52.9% of the prescribed drugs to pregnant women assisted 
in the National Program of Prenatal and Postpartum Follow-
up in a municipality of Rio Grande do Sul in 2010. The 
prescribed products are mostly of systemic use, miconazole 
vaginal cream, cephalexin 500 mg, metronidazole vaginal 
cream, azithromycin 500 mg, and amoxicillin 500 mg were 
the mostly prescribed. The majority of the products belong 
to the risk category B during pregnancy, which according to 
the FDA there is no direct evidence of risk to the fetus, but 
animal studies showed some fetal risk.
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